BIIB vs. TEVA, AEP, PNW, VRTX, REGN, GILD, ALNY, BMRN, NBIX, and INCY
Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Teva Pharmaceutical Industries (TEVA), American Electric Power (AEP), Pinnacle West Capital (PNW), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Incyte (INCY).
Teva Pharmaceutical Industries (NYSE:TEVA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.
Biogen has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Biogen received 465 more outperform votes than Teva Pharmaceutical Industries when rated by MarketBeat users. Likewise, 71.93% of users gave Biogen an outperform vote while only 67.61% of users gave Teva Pharmaceutical Industries an outperform vote.
Biogen has a net margin of 12.07% compared to Biogen's net margin of -2.88%. Biogen's return on equity of 37.33% beat Teva Pharmaceutical Industries' return on equity.
Teva Pharmaceutical Industries currently has a consensus price target of $15.75, suggesting a potential downside of 6.97%. Biogen has a consensus price target of $286.50, suggesting a potential upside of 27.37%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Biogen is more favorable than Teva Pharmaceutical Industries.
In the previous week, Biogen had 12 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 32 mentions for Biogen and 20 mentions for Teva Pharmaceutical Industries. Biogen's average media sentiment score of 0.38 beat Teva Pharmaceutical Industries' score of 0.37 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Biogen has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500.
Summary
Biogen beats Teva Pharmaceutical Industries on 12 of the 18 factors compared between the two stocks.
Get Biogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
